By Dr Adam Jacob Bryant

Book Chapters

Bryant A, 2021, 'Elotuzumab', in Resistance to Targeted Anti-Cancer Therapeutics, Springer International Publishing, pp. 73 - 82, http://dx.doi.org/10.1007/978-3-030-73440-4_6

Journal articles

Al‐Ammari M; Hsu D; Bryant A, 2024, 'Myeloma‐associated hemophagocytic lymphohistiocytosis – A comprehensive case study and a novel chemotherapy‐free approach with anakinra', eJHaem, http://dx.doi.org/10.1002/jha2.975

Hungria V; Robak P; Hus M; Zherebtsova V; Ward C; Ho PJ; Ribas de Almeida AC; Hajek R; Kim K; Grosicki S; Sia H; Bryant A; Pitombeira de Lacerda M; Aparecida Martinez G; Sureda Balarí AM; Sandhu I; Cerchione C; Ganly P; Dimopoulos M; Fu C; Garg M; Abdallah A-O; Oriol A; Gatt ME; Cavo M; Rifkin R; Fujisaki T; Mielnik M; Pirooz N; McKeown A; McNamara S; Zhou X; Nichols M; Lewis E; Rogers R; Baig H; Eccersley L; Roy-Ghanta S; Opalinska J; Mateos M-V; DREAMM-7 Investigators , 2024, 'Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma.', N Engl J Med, http://dx.doi.org/10.1056/NEJMoa2405090

Tong MH; Kwok A; Walsh A; Heydon P; Koh ES; McNamara N; Bryant A, 2024, 'Isolated Ocular Relapse of Acute Myeloid Leukaemia Post Allogeneic Stem Cell Transplant', Case Reports in Ophthalmological Medicine, 2024, pp. 2235819, http://dx.doi.org/10.1155/2024/2235819

Li EW; Jones E; Bryant C; King T; Talaulikar D; Ng JY; Bryant A; Ridha Z; Doo NW; Menzies A; Ling S; Ho SJ; Abadir E; Vanguru V; Joshua D; Ho PJ, 2024, 'A single-day polychemotherapy regimen with proteasome inhibitor combinations for relapsed/refractory myeloma in the era of novel therapies', European Journal of Haematology, http://dx.doi.org/10.1111/ejh.14266

Ponraj R; Bryant A; Dunlop L; Range H; Cobrador C; Ling S; Hsu D, 2023, 'Carfilzomib-induced thrombotic microangiopathy (TMA): an under-recognised spectrum of disease from microangiopathic haemolysis to subclinical TMA', Blood Cancer Journal, 13, http://dx.doi.org/10.1038/s41408-023-00885-9

Plesner T; Harrison SJ; Quach H; Lee C; Bryant A; Vangsted A; Estell J; Delforge M; Offner F; Twomey P; Choeurng V; Li J; Hendricks R; Ruppert SM; Sumiyoshi T; Miller K; Cho E; Schjesvold F, 2023, 'Phase I Study of Safety and Pharmacokinetics of RO7297089, an Anti-BCMA/CD16a Bispecific Antibody, in Patients with Relapsed, Refractory Multiple Myeloma', Clinical Hematology International, 5, pp. 43 - 51, http://dx.doi.org/10.1007/s44228-022-00023-5

McCaughan GJ; Verma A; Ling S; Lavee O; Moore JJ; Bryant A, 2021, 'Weekly cyclophosphamide, subcutaneous bortezomib and dexamethathasone (CyBorD) for initial treatment of transplant-eligible patients with multiple myeloma: experience of two transplant centres', Bone Marrow Transplantation, 56, pp. 738 - 740, http://dx.doi.org/10.1038/s41409-020-01086-9

Othman J; Greenwood M; Moore J; Larsen S; Watson AM; Arthur C; Bhattacharyya A; Bilmon I; Blyth E; Bryant A; Bryant C; Dunlop L; Fay K; Gibson J; Hamad N; Kerridge I; Kwan J; Ma D; Micklethwaite K; Milliken S; Panicker S; Stevenson W; Withers B; Wilcox L; Tran S; Gottlieb DJ, 2020, 'Unrelated Donor Transplant Recipients Given Thymoglobuline Have Superior GRFS When Compared to Matched Related Donor Recipients Undergoing Transplantation without ATG', Biology of Blood and Marrow Transplantation, 26, pp. 1868 - 1875, http://dx.doi.org/10.1016/j.bbmt.2020.06.030

Palma CA; Al Sheikha D; Lim TK; Bryant A; Vu TT; Jayaswal V; Ma DDF, 2014, 'MicroRNA-155 as an inducer of apoptosis and cell differentiation in Acute Myeloid Leukaemia', Molecular Cancer, 13, http://dx.doi.org/10.1186/1476-4598-13-79

Dalal BI; Al Mugairi A; Pi S; Lee SY; Khare NS; Pal J; Bryant A; Vakil AP; Lau S; Abou Mourad YR, 2014, 'Aberrant expression of CD13 identifies a subgroup of standard-risk adult acute lymphoblastic leukemia with inferior survival.', Clin Lymphoma Myeloma Leuk, 14, pp. 239 - 244, http://dx.doi.org/10.1016/j.clml.2013.10.003

Bryant A; Nivison-Smith I; Pillai ES; Kennedy G; Kalff A; Ritchie D; George B; Hertzberg M; Patil S; Spencer A; Fay K; Cannell P; Berkahn L; Doocey R; Spearing R; Moore J, 2014, 'Fludarabine Melphalan reduced-intensity conditioning allotransplanation provides similar disease control in lymphoid and myeloid malignancies: analysis of 344 patients', Bone Marrow Transplantation, 49, pp. 17 - 23, http://dx.doi.org/10.1038/bmt.2013.142

Bilmon I; Nivison-Smith I; Hertzberg M; Ritchie D; Greenwood M; Spencer A; Kennedy G; Bryant A; Moore J, 2014, 'Outcomes following second allogeneic haematopoietic transplants using fludarabine–melphalan conditioning', Bone Marrow Transplantation, 49, pp. 852 - 853, http://dx.doi.org/10.1038/bmt.2014.23

Bryant A; Palma CA; Jayaswal V; Yang YH; Lutherborrow MA; Ma DD, 2012, 'miR-10a is aberrantly overexpressed in Nucleophosmin1 mutated acute myeloid leukaemia and its suppression induces cell death', Molecular Cancer, 11, pp. 8, http://dx.doi.org/10.1186/1476-4598-11-8

Loi TH; Campain A; Bryant AJ; Molloy T; Lutherborrow MA; Turner J; Yang YH; Ma DD, 2011, 'Discriminating lymphomas and reactive lymphadenopathy in lymph node biopsies by gene expression profiling', BMC Medical Genomics, 4, pp. 1 - 10, http://www.biomedcentral.com/1755-8794/4/27

Lutherborrow MA; Bryant AJ; Jayaswal V; Agapiou DJ; Palma CA; Yang YH; Ma DD, 2011, 'Expression profiling of cytogenetically normal acute myeloid leukemia identifies MicroRNAs that target genes involved in monocytic differentiation', American Journal of Hematology, 86, pp. 2 - 11, http://dx.doi.org/10.1002/ajh.21864

Sasson SC; Smith S; Seddiki N; Zaunders J; Bryant AJ; Koelsch KK; Weatherall CJ; Munier CM; McGinley C; Yeung J; Mulligan S; Moore JJ; Cooper DA; Milliken ST; Kelleher AD, 2010, 'IL-7 receptor is expressed on adult pre-B-cell acute lymphoblastic leukemia and other B-cell derived neoplasms and correlates with expression of proliferation and survival markers', Cytokine, 50, pp. 58 - 68

Bryant A; Lutherborrow MA; Ma DD, 2009, 'The clinicopathological relevance of microRNA in normal and malignant haematopoiesis', Pathology, 41, pp. 204 - 213

Bryant A; Milliken ST, 2008, 'Successful reduced-intensity conditioning allogeneic HSCT for HIV-related primary effusion lymphoma', Biology of Blood and Marrow Transplantation, 14, pp. 601 - 602, http://dx.doi.org/10.1016/j.bbmt.2008.01.010

Bryant A; Low J; Austin SA; Joseph JE, 2008, 'Timely diagnosis and management of heparin-induced thrombocytopenia in a frequent request, low incidence single centre using clinical 4T`s score and particle gel immunoassay', British Journal of Haematology, 143, pp. 721 - 726

Bryant A; Moore J, 2006, 'Rituximab and its potential for the treatment of rheumatoid arthritis', Therapeutics and Clinical Risk Management, 2, pp. 207 - 212, http://dx.doi.org/10.2147/tcrm.2006.2.2.207

Conference Abstracts

Bryant C; Abadir E; Doo NW; Bryant A; McCaughan G; Yang S; Vanguru V; King T; Joshua D; Ho PJ, 2023, 'P-070 Failure to clear circulating tumor cells after one week of daratumumab, bortezomib and dexamethasone is associated with a reduced progression-free survival for myeloma patients', in Clinical Lymphoma Myeloma and Leukemia, Elsevier BV, Vol. 23, pp. S73 - S73, http://dx.doi.org/10.1016/s2152-2650(23)01688-9

Li E; Bryant C; Jones E; King T; Talaulikar D; Ng J; Bryant A; Ridha Z; Doo NW; Ling S; Ho PJ; Joshua D, 2023, 'P-289 The efficacy and safety of prednisone, cyclophosphamide, doxorubicin and carmustine (PCAB) in relapsed/refractory multiple myeloma in the era of novel therapy, including as a bridge to CAR-T therapy', in Clinical Lymphoma Myeloma and Leukemia, Elsevier BV, Vol. 23, pp. S196 - S196, http://dx.doi.org/10.1016/s2152-2650(23)01907-9

Plesner T; Harrison SJ; Quach H; Lee CH; Bryant A; Vangsted AJ; Estell J; Delforge M; Offner F; Twomey P; Choeurng V; Li J; Hendricks R; Sumiyoshi T; Miller K; Choi E; Schjesvold FH, 2021, 'A Phase I Study of RO7297089, a B-Cell Maturation Antigen (BCMA)-CD16a Bispecific Antibody in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)', in BLOOD, AMER SOC HEMATOLOGY, Vol. 138, http://dx.doi.org/10.1182/blood-2021-147418Get

McCaughan GJ; Tran S; Durrant S; Harrison SJ; Morton J; Horvath N; Spencer A; Kerridge IH; Er JAK; Barge L; Bryant A; Filshie RJ; Choong E; Lai HC; Tiley C; Mills AK; Butler A; Moore J; Hertzberg M; Kennedy GA; Ho PJ; Sidiqi MH; Bashford J; Routledge D; Taylor K; Lee CH; Kalff A; Xia W; Hamad N, 2020, 'Trends in Outcomes in Australia and New Zealand in Autologous Stem Cell Transplantation in Older Patients with Multiple Myeloma: An Australasian Bone Marrow Transplant Recipient Registry Study', in Blood, American Society of Hematology, Vol. 136, pp. 11 - 12, http://dx.doi.org/10.1182/blood-2020-138991

McCaughan GJ; Verma A; Ling S; Lavee O; Moore J; Bryant A, 2020, 'Weekly Cyclophosphamide, Subcutaneous Bortezomib and Dexamethathasone (CyBorD) for Initial Treatment of Transplant Eligible Patients with Multiple Myeloma: Experience of Two Transplant Centres', in Blood, American Society of Hematology, Vol. 136, pp. 42 - 43, http://dx.doi.org/10.1182/blood-2020-139269

Haack R; Mallik S; Sungala N; Bryant A; Ho LL; Motum P, 2019, 'COPPER DEFICIENCY: DON'T YOU FORGET ABOUT ME.', in INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, WILEY, Vol. 41, pp. 68 - 68, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000487566000106&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Watson A-M; Bryant A; Davison S; Ling S; Levy M, 2016, 'Treatment of Otherwise Ineligible Donors for Hepatitis B Prior to Matched Sibling Allogeneic Stem Cell Transplant', in BONE MARROW TRANSPLANTATION, NATURE PUBLISHING GROUP, SPAIN, Valencia, Vol. 51, pp. S140 - S140, presented at 42nd Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation, SPAIN, Valencia, 03 April 2016 - 06 April 2016, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000373357600241&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Bryant A; Kershaw G; Zebeljan D; Motum P; Das R, 2013, 'Factor VIII inhibitor and pulmonary embolism developing in a patient after meningioma resection: clinical and laboratory aspects', in JOURNAL OF THROMBOSIS AND HAEMOSTASIS, WILEY-BLACKWELL, Vol. 11, pp. 1021 - 1021, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000331833604400&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Dalal BI; Al Mugairi A; Bryant A; Lau S; Pi S; Khare NS; Pal J; Mourad YA, 2013, 'Aberrant Expression of Myeloid Antigens Identifies a Subgroup of Standard-Risk Adult Acute Lymphoblastic Leukemia Patients with Short Survival', in Biology of Blood and Marrow Transplantation, Elsevier BV, Vol. 19, pp. S223 - S224, http://dx.doi.org/10.1016/j.bbmt.2012.11.268

Bryant AJ; Palma CA; Lutherborrow M; Jayaswal V; Yang YH; Ma D, 2011, 'Knockdown of MicroRNA-10a in Acute Myeloid Leukaemia Cells Bearing the Nucleophosmin1 Mutation Causes Cell Death and Reduced Clonogenicity', in BLOOD, AMER SOC HEMATOLOGY, CA, San Diego, Vol. 118, pp. 599 - 600, presented at 53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)/Symposium on the Basic Science of Hemostasis and Thrombosis, CA, San Diego, 10 December 2011 - 13 December 2011, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000299597101636&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Bryant AJ; Pillai E; Kennedy G; Kalff A; Ritchie D; George B; Hertzberg M; Patil SS; Spencer A; Fay K; Cannell P; Berkahn L; Doocey R; Spearling R; Nivison-Smith I; Moore J, 2011, 'A Retrospective Analysis of 344 Fludarabine Melphalan RIC Allogeneic Stem Cell Transplants for Myeloid and Lymphoid Malignancies In Australia and New Zealand 1998–2008,', in Blood, American Society of Hematology, Vol. 118, pp. 4143 - 4143, http://dx.doi.org/10.1182/blood.v118.21.4143.4143

Palma CA; Tonna E; Bryant AJ; Jayaswal V; Agapiou D; Yang YH; Ma D; Lutherborrow M, 2011, 'MicroRNA Expression in Acute Myeloid Leukaemia and Their Effects on the Differentiation of Acute Myeloid Leukaemia Cells', in Blood, American Society of Hematology, Vol. 118, pp. 2430 - 2430, http://dx.doi.org/10.1182/blood.v118.21.2430.2430

Bryant A; Moore JJ; Dodds AJ; Milliken ST; Fay K; Ma DD, 2007, 'Pneumonitis and renal toxicity with sirolimus based GVHD prophylaxis for RIC allogeneic', in Haematologica - the Hematology Journal, Ferrata Storti Foundation, Vol. 92, pp. 516 - 516

Back to profile page